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Influence of single and multiple doses of amifostine
on the efficacy and the pharmacokinetics of carboplatin
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Summary We have previously reported that amifostine potentiates the anti-tumour activity of carboplatin in mice. The present study was
carried out in well-established human ovarian cancer xenografts OVCAR-3, A2780 and FMa grown subcutaneously in the nude mouse. It was
found that a single dose of amifostine resulted in a higher increase in the anti-tumour activity of carboplatin than three doses of amifostine. A
single dose of amifostine increased the AUC (area under the curve) values of total platinum in plasma ultrafiltrate (30.1 vs 18.2 gM X h), liver
(307.7 vs 236.4 nmol g-1 x h), kidney (500.8 vs 368.3 nmol g-' x h) and OVCAR-3 tumour tissue (184.0 vs 146.8 nmol g-' x h). Despite this
increase in total platinum, a decrease in platinum (Pt)-DNA adduct levels was observed in liver, kidney and bone marrow, which was
significant in liver. In tumour tissue an insignificant increase in Pt-DNA adduct levels, specifically the Pt-GG adduct, was observed after
treatment with a single dose of amifostine, which may explain the increase in anti-tumour activity. The increase in the AUC of total platinum
was probably caused by a reduction in body temperature, which was most severe after three doses of amifostine. The extreme hypothermia
may be the reason that three doses of amifostine resulted in less potentiation of the efficacy of carboplatin.
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Carboplatin [cis-diammine(1,1-cyclobutanedicarboxylato)plat-
inum(II)] was developed as a second-generation platinum compound
with less nephrotoxicity than cisplatin. Its anti-tumour activity is
assumed toresult from the formation ofplatinum (Pt)-DNA adducts.
The clinical use of carboplatin is limited by myelosuppression at a
dose in the steep part of the dose-response curve. Therefore, much
effort has been put into reducing the toxic side-effects to allow the
administration ofhigher doses ofcarboplatin.
Amifostine [Ethyol, WR-2721, S-2-(3-aminopropylamino)-
ethylphosphorothioic acid], initially developed as aradioprotector,
is approved for use as a protector against chemotherapy-induced
toxicities in the USA and Europe (van derVijgh and Peters, 1994).
A selective protection against the side-effects of platinum
compounds has been observed in clinical and preclinical studies
(Treskes et al, 1992a, 1994; Capizzi, 1994; van der Vijgh and
Peters, 1994). Amifostine is the prodrug of the aminothiol
compound WR-1065 (Figure 1), which inhibits DNA platination
(Treskes et al, 1992b). The selective protection is based on the
preferential formation and uptake ofthis active metabolite in non-
tumour tissues (Yuhas, 1980; Brown et al, 1988; Calabro-Jones et
al, 1988; Shaw et al, 1988).
In vitro experiments have shown that the modifying action of
amifostine was protection rather than rescue from toxicity
(Treskes et al, 1992b). Considering these results and the rapid
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uptake and clearance ofWR-1065 by non-tumour tissues after the
(i.p. or i.v.) administration of amifostine (Utley et al, 1984; Shaw
et al, 1988, 1994), optimal protection would be achieved when
amifostine is administered shortly before the platinum drug.
Efficient protection against cisplatin-induced nephrotoxicity was
observed in mice when amifostine was administered 5 min or 30
min before cisplatin (Treskes et al, 1992a). Protection against
carboplatin-induced myelotoxicity was more obvious when
amifostine was given 5 min instead of 30 min before carboplatin
(Treskes et al, 1994). With respect to the long elimination half-life
of non-protein-bound carboplatin in comparison with amifostine
(van der Vijgh, 1991), greater myeloprotection might be achieved
by multiple doses of amifostine when combined with carboplatin.
Such an approach is incorporated into clinical trials in which
amifostine is given three times, just before and 2 and 4 h after
carboplatin (Betticher et al, 1995; Vermorken et al, 1995). To date,
clinical data are available for only a small number ofpatients. The
Amifostine
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Figure 1 Structural formulas of amifostine, its active metabolite WR-1065
and the disulphides [with WR-1065 itself or with endogenous thiols (RSH)]
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results do suggest that amifostine can reduce the duration of
thrombocytopenia and hospitalization (Betticher et al, 1995).
The use ofmodulating agents can only be successful when these
compounds do not interfere with the anti-tumour activity of the
cytotoxic agent. Studies in tumour-bearing nude mice have
demonstrated that amifostine administered 5 min before the plat-
inum compound did not reduce the anti-tumour efficacy of
cisplatin (Treskes et al, 1992a) and carboplatin (Treskes et al,
1994). In the case of carboplatin even a potentiation of the anti-
tumour activity was noticed when amifostine was given once,
whereas amifostine itselfdid not affect tumour growth (Treskes et
al, 1994). However, the influence of multiple doses of amifostine
on the anti-tumour activity ofcarboplatin was not studied.
In the present experiments we investigated the influence of
multiple doses of amifostine on the efficacy of carboplatin in
tumour-bearing nude mice. We also investigated the influence of
one and three doses of amifostine on the pharmacokinetics of
carboplatin and the formation ofPt-DNA adducts in order to inter-
pret the efficacy of carboplatin in the presence of amifostine.
Furthermore, we determined the influence of a single dose and
multiple doses ofamifostine on thebody temperature in nude mice.
MATERIALS AND METHODS
Chemicals
Paraplatin (150 mg of lyophilized carboplatin and 150 mg of
mannitol) was obtained fromBristol-Myers Squibb (Woerden, The
Netherlands) and reconstituted with 15 ml of glucose 5% before
use. Amifostine (500 mg oflyophilized WR-2721 and 500 mg of
mannitol) was obtained from US Bioscience (WestConshohocken,
PA, USA) and reconstituted with 9.3 ml of sterile water. Before
use the compound was further diluted with 0.9% sodium chloride.
Xenografts and treatment schedules
Female athymic nude mice (Harlan/Cpb, Zeist, The Netherlands),
housed and fed as described previously (Boven et al, 1985), were
inoculated subcutaneously (s.c.) in both flanks with fragments
(2-3 mm in diameter) of the human ovarian cancer xenografts
OVCAR-3, A2780 or FMa. OVCAR-3 is a poorly differentiated
serous adenocarcinoma, A2780 an undifferentiated carcinoma and
FMa a poorly differentiated mucinous adenocarcinoma.
Treatment was started when tumours had reached approxi-
mately 300 mm3 in size in the pharmacokinetic study and 50-150
mm3 in the anti-tumour activity studies (designated as day 0).
Amifostine injections were given i.p., whereas carboplatin was
administered in a tail vein. Drug doses were derived from previous
experiments in which carboplatin 60 mg kg-' given on days 0 and
7 was considered the maximum tolerated dose (MTD) allowing
10% weight loss within 2 weeks after the first injection (Treskes et
al, 1994). One injection of amifostine (200 mg kg-') given 5 min
before carboplatin enhanced the anti-tumour activity in the
OVCAR-3 xenograft model. In those experiments the MTD of
carboplatin preceded by one injection of 200 mg kg-' amifostine
could be increased to 90 mg kg-'. In the current study, mice were
treated with 60 mg kg-' carboplatin alone or in combination with a
single or three doses of 200 mg kg-' amifostine to investigate the
influence ofamifostine on the anti-tumour activity and pharmaco-
kinetics ofcarboplatin. Amifostine was administered 5 min before
carboplatin as a single dose or 5 min before and 2 and 4 h after
carboplatin when administered three times. The 90 mg kg-' dose of
carboplatin was also investigated for its anti-tumour activity when
administered under the protection ofthree doses ofamifostine.
Anti-tumour activity
To investigate the influence of three doses of amifostine on the
anti-tumour activity of carboplatin, mice bearing bilateral
OVCAR-3, A2780 or FMa xenografts (5-6 mice per group) were
treated on days 0 and 7 with 60 mg kg-' carboplatin alone or in
combination with three times 200 mg kg-' amifostine. A control
group (untreated) and a group treated with three doses of amifos-
tine alone were included. In OVCAR-3- and FMa-bearing mice an
additional group was treated on days 0 and 7 with 90 mg kg-'
carboplatin in combination with three doses of amifostine. In a
second experiment the influence of one vs three doses of amifos-
tine on the anti-tumour activity of carboplatin 60 mg kg-' was
investigated in mice bearing OVCAR-3 or FMa xenografts,
treated on days 0 and 7. In this experiment, additional groups of
mice were control (untreated) or treated with carboplatin alone.
In the first experiment mice were weighed twice a week and in
the second once (OVCAR-3 and FMa xenografts) ortwice (A2780
xenografts) a week. Tumours were measured weekly with a slide
caliper by the same observer. Tumour volume was calculated as
length x width x height x 0.5 in mm3 and expressed relative to the
volume at the start of the treatment. The anti-tumour activity was
expressed as the percentage ofgrowth inhibition [1 - (mean ofthe
relative volumes of the treated tumours divided by that of the
control tumours) x 100%]. In principle this was calculated on the
day of its maximum value, reached within 5 weeks after the last
day of treatment. In addition, the number of days for a tumour to
reach four times its volume from that at the start of treatment
(TDIO4), was calculated.
Pharmacokinetics
Mice bearing OVCAR-3 xenografts were treated with 60 mg kg-'
carboplatin alone or in combination with 1 x or 3 x 200 mg kg-'
amifostine. Of each group, three mice per time point were bled
from the axillary vein under ether anaesthesia at 0.5, 1, 1.7, 3, 5, 8,
12 or 24 h after carboplatin administration. Thereafter, liver,
kidney and tumours were removed. Bone marrow was collected by
flushing both femurs with RPMI medium and pooled from the
three mice per time point ofeach group. The plasma samples were
ultrafiltrated by MPS-1 systems provided with YMT filters
(Amicon, Capelle a/d IJssel, The Netherlands). Plasma ultrafiltrate
and parts of liver, kidney and tumours were stored at -20°C until
analysis of total platinum. Bone marrow and parts ofliver, kidney
and tumours were stored at -80°C until analysis of Pt-DNA
adducts.
For platinum analysis the samples were pretreated as follows.
Plasma ultraflltrate samples were diluted 1:1 with 0.15 M sodium
chloride/0.4 M hydrochloric acid before measurement of the plat-
inum concentration. Tissue samples of 100 mg were digested in
1.0 ml of concentrated nitric acid in a Teflon bomb at 170°C for
2 h. After cooling, the samples were transferred to glass tubes and
evaporated under nitrogen after addition of 20 gl of 1.7 M sodium
chloride. The residues were reconstituted in 250 pl of 0.15 M
sodium chloride/0.2 M hydrochloric acid. Platinum concentrations
were analysed by flameless atomic absorption spectrophotometry
using a Spectra AA-300 Zeeman AAS (Varian, Houten, The
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Table 1 Efficacy and toxicity of carboplatin ± amifostine in well-established s.c. human ovarian cancer xenografts in female nude mice (n 2 5 per group) treated
weekly x 2 with 3 x 200 mg kg-' amifostine, 60 mg kg-' carboplatin, 60 mg kg-' carboplatin + 3 x 200 mg kg-' amifostine or 90 mg kg-' carboplatin + 3 x 200 mg kg-'
amifostine
Xenograft Treatment Anti-tumour activity Toxicity
Carboplatin Amifostine Growth Inhibition (%) TDI,4 Maximum Weight on Toxic
(mg kg-' i.v.) (mg kg-' i.p.) (Day) s.e.m.)a weightlosSb day 14b deaths
OVCAR-3 - - NA NA 9.9 ± 0.8 NA 106.3 ± 3.5 0/6
- 3 x200 0.0(28) 0.0(35) 11.0±0.4 5.5±2.4 105.4±2.3 1/6
60 - 93.2 (28) 89.0 (35) 42.8 ± 2.2 0.3 ± 2.9 104.8 ± 3.8 0/5
60 3 x 200 92.2 (28) 88.2 (35) 44.4 ± 2.1 9.5 ± 2.8 98.8 ± 2.0 1/6
90 3 x200 97.7 (28) 98.2 (35)c 62.7±1.3c 15.9 ±5.4 92.1 ±4.1 1/6
A2780 - - NA NA 4.6 ±0.6 NA 118.5 ±13.4 0/6
- 3x200 31.1 (11) 17.4 (14) 6.4± 1.3 4.6±4.8 108.0±4.9 2/6
60 - 28.8 (11) 14.0 (14) 6.1 ±0.8 0.6±3.2 105.6±9.8 0/5
60 3 x 200 21.6(11) 9.0(14) 5.1±1.1 11.4 ±11.7 97.6 ±3.0 1/6
FMa - - NA NA 12.1 ±2.3 NA 104.9 ± 6.3 0/6
- 3 x200 20.3(29) 21.5(36) 13.8 ±1.3 10.7±5.5 96.8 ±3.9 0/6
60 - 90.3 (29) 89.3 (36) 46.6 ± 3.2 6.6 ± 4.9 94.6 ± 7.9 0/6
60 3x200 93.3 (29) 92.1 (36) 46.8± 1.8 13.5±6.1 92.7±8.0 0/6
90 3 x 200 97.4 (29) 98.0 (36)3 60.9 ± 4.33 20.3 ± 6.4 87.1 ± 9.0 1/6
aTme after start of treatment until a relative volume of 4 was reached (days). bCalculated as a percentage (± s.d.) of the weight at the start of treatment.
cp< 0.02 compared with 60 mg kg-' carboplatin, P< 0.01 compared with 60 mg kg-' carboplatin and 3 x amifostine. NA, not applicable.
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Figure 2 Relative volumes of well-established s.c. OVCAR-3 xenografts
grown in female nude mice treated twice (indicated by arrows) with
60 mg kg-' carboplatin i.v. alone (*), in combination with 1x 200 mg kg-'
amifostine i.p. (O) or 3 x 200 mg kg-' amifostine i.p. (E]1) in comparison with
control mice (0)
Netherlands). Standards of blank plasma ultrafiltrate and tissue
spiked with carboplatin were treated in the same way as the
samples.
To determine Pt-DNAadducts, tissue samples wereground to cell
suspensions in 2 ml ofTris-EDTA supplemented with 0.5 M ammon-
ium bicarbonate. DNA was isolated as described elsewhere
(Blommaert et al, 1995). From the liver samples the cell nuclei were
isolated before DNA isolation according to a previously described
method (Roggeband et al, 1993). After digestion the isolated DNA
samples were chromatographed on a Mono Q anion-exchange
column (Pharmacia, Woerden, The Netherlands) and appropriate
column fractions were analysed in a competitive enzyme-linked
immunosorbent assay (ELISA) (Fichtinger-Schepman et al, 1987).
With this procedure four platinum-containing (di)nucleotides could
be identified (Fichtinger-Schepman et al, 1987; Blommaert et al,
1995): Pt-GG and Pt-AG (bifunctional adducts of carboplatin with
two adjacent guanines orwith adenine adjacent to guanine), G-Pt-G
[bifunctional adduct ofcarboplatin with two non-adjacent guanines
eitherin the same strand (intrastrand crosslink) orwithtwoguanines
in the opposite DNA strands (interstrand crosslink)] and Pt-G
(carboplatin monofunctionally bound to aguanine residue).
Area under the curve (AUC) values of the concentration-time
curves of total platinum and of Pt-DNA adducts were calculated
from the mean concentrations at each time point, over 0.5-24 h
after the carboplatin administration, using the trapezoidal rule.
Temperature
Non-tumour-bearing nude mice were either injected with
60 mg kg-' carboplatin alone (n = 3) or in combination with
200 mg kg-' amifostine, administered once (n = 3) or three times
(n = 3). Temperature changes were monitored for 24 h by
measuring body temperature intrarectally by a Lameris Ellab-
Instruments thermocouple (Lameris, Utrecht, The Netherlands).
Statistics
Results ofthe pharmacokinetic and the anti-tumouractivity studies
were evaluated with Student's t-test.
RESULTS
Anti-tumour activity
The anti-tumour activity ofcarboplatin in the three human ovarian
cancer xenografts was expressed as the percentage ofgrowth inhi-
bition and the TDI<4 (Table 1). Carboplatin at the MTD of
60 mg kg-' was active in OVCAR-3 and FMa xenografts, whereas
no significant influence on the growth of A2780 tumours was
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Table 2 Efficacy and toxicity of carboplatin ± amifostine in well-established s.c. xenografts OVCAR-3 and FMa in female nude mice (six per
group) treated weekly x 2 with 60 mg kg-' carboplatin alone or in combination with 1 x 200 mg kg-' amifostine or 3 x 200 mg kg-' amifostine
Xenograft Treatment Anti-tumour activity Toxicity
Carboplatin Amifostine Growth inhibition(%) TDi..,4 Weight Toxic
(mg kg-1 l.v.) (mg kg-1 i.p.) (Day) (± s.e.m.)a on day 14b deaths
OVCAR-3 - - NA NA 9.0 ± 0.8 109.7 ± 4.7 0/6
60 - 88.5 (20) 92.4 (27) 33.5 ± 1.1 106.0 ± 2.7 0/6
60 1 x200 92.7 (20)3 96.7 (27) 43.7 ± 1.4c 104.0 ± 4.0 0/6
60 3 x 200 89.9 (20) 95.2 (27) 38.8 ± 1.3d 98.3 ± 3.9 0/6
FMa - - NA NA 11.1 ±0.8 103.2± 1.6 0/6
60 - 79.2 (21) 76.0 (28) 32.4 ± 2.0 95.6 ± 3.4 0/6
60 1 x200 81.5 (21) 82.0 (28) 36.8 ± 2.3 98.4 ± 2.0 0/6
60 3 x 200 81.5 (21) 78.0 (28) 35.9 ± 1.9 88.2 ± 6.0 0/6
aTime after start of treatment until a relative volume of 4 was reached (days). bCalculated as a percentage (± s.d.) of the weight at the start of
treatment. cp< 0.001 compared with 60 mg kg-' carboplatin. P< 0.02 compared with 60 mg kg-' carboplatin and 3 x amifostine. dp< 0.01
compared with 60 mg kg-' carboplatin. NA, not applicable.
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Figure 3 Platinum concentration-time curves and AUC values (from 0.5 to 24 h) in plasma ultrafiltrate (A), liver (B) kidney (C) and OVCAR-3 (D) tumourtissue
from mice treated with 60 mg kg-' carboplatin alone (0, C) or in combination with 1 x 200 mg kg-' amifostine (0, C + 1A) or 3 x 200 mg kg-' amifostine (U, C +
3A). IP< 0.05 compared with treatment C; 2p< 0.05 compared with treatment C + IA
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90 mg kg-' carboplatin and three doses ofamifostine was the most
toxic (maximum weight loss 15.9% and 20.3% respectively),
followed by 60 mg kg-' carboplatin plus three doses of amifostine
(9.5% and 13.5% respectively). Amifostine given three times
induced more weight loss than when given only once (latter data
not shown). Except for the carboplatin 90 mg kg-1 plus three doses
of amifostine schedule, mice had recovered from weight loss on
day 14 of the treatment experiment. In Table 2 it is shown that
recovery on day 14 was better in mice receiving carboplatin plus
one dose of amifostine than in animals receiving three doses of
amifostine. Toxic deaths were observed in mice receiving sched-
ules that contained three doses of amifostine, even without carbo-
platin. Animals died within 4 days after the injections and this was
preceded by excessive weight loss.
Figure 4 AUC values of Pt-DNA adducts in liver, kidney, OVCAR-3 tumour
tissue and bone marrow from 0.5 to 24 h after treatment with carboplatin
alone (C) or in combination with 1 x 200 mg kg-' amifostine (C + 1A) or
3 x 200 mg kg-' amifostine (C + 3A). 'P< 0.05 compared with treatment C;
2p< 0.005 compared with treatment C + 1A
observed. In OVCAR-3 and FMa xenografts the administration of
a 1.5-fold increased dose of carboplatin (90 mg kg-'), which can
only be administered under the protection of amifostine (Treskes
et al, 1994), was significantly more effective than 60 mg kg-'
carboplatin alone or combined with amifostine (P < 0.01).
Amifostine, given as a single dose (Treskes et al, 1994) or given
three times, did not have any anti-tumour activity. When
60 mg kg-' carboplatin was combined with three doses of amifos-
tine no significant change in growth inhibition was observed when
compared with 60 mg kg-' carboplatin alone.
Our results on carboplatin and three doses of amifostine did not
correspond with the earlier reported significant potentiation of the
anti-tumour activity of carboplatin by one dose of amifostine
(Treskes et al, 1994). A second experiment was performed in
which we investigated the presence of a dose- or a schedule-
dependent interaction between amifostine and carboplatin.
Therefore, we examined the influence of one vs three doses of
amifostine on the anti-tumour activity ofcarboplatin in OVCAR-3-
and FMa-bearing nude mice (Figure 2, Table 2). When carboplatin
was combined with three doses of amifostine a slight increase in
the anti-tumour activity was observed in OVCAR-3-bearing mice
when compared with carboplatin alone (TDI,4 38.8 vs 33.5 days,
P < 0.02). However, when only one dose of amifostine was
administered a more pronounced potentiation of the anti-tumour
activity of carboplatin was observed in OVCAR-3-bearing mice
when compared with carboplatin alone (growth inhibition 92.7%
vs 88.5% and TDI 4 43.7 vs 33.5 days, P < 0.001), which was
comparable to that described before (Treskes et al, 1994). In
FMa-bearing mice the same trend was observed, although the
difference was not significant (growth inhibition 82.0% vs 76.0%
and TD}14 36.8 vs 32.4 days).
As a measure for toxicity, maximum weight loss and the body
weight on day 14, both expressed as a percentage of the weight at
the start of treatment, as well as the number of toxic deaths have
been summarized in Tables and 2. Nadir weight loss after treat-
ment with carboplatin and amifostine was observed 3-4 days after
treatment (Treskes et al, 1994). In Table 2 maximum weight loss
was not documented, because the weight was measured weekly.
In OVCAR-3- and FMa-bearing nude mice the combination of
Pharmacokinetics
Concentration-time curves of platinum in plasma ultrafiltrate and
tissues from OVCAR-3-bearing nude mice after treatment with
carboplatin alone or in combination with one or three doses of
amifostine are shown in Figure 3. In plasma ultrafiltrate as well as
in normal and tumour tissues, platinum concentrations were higher
after treatment with carboplatin and amifostine than with carbo-
platin alone, resulting in an increase in AUC values as shown in
Figure 3. In plasma ultrafiltrate, increases of approximately 1.7-
fold and 2-fold were observed when compared with carboplatin
alone, of which only the 2-fold increase after three doses of
amifostine was statistically significant (P < 0.05). In tissues a
significant increase of approximately 1.3-fold and 1.5-fold (P <
0.05) was observed after treatment with a single and three doses of
amifostine, respectively. The difference between the AUC values
after the single- and the three-dose schedule was only significant
in liver (P < 0.05).
The AUC values ofPt-DNA adduct levels are given in Figure 4.
Each column shows the AUC value of the total DNA platination,
i.e. the sum ofthe four types ofadducts determined in the digested
DNA samples. In the normal tissues the total Pt-DNA adduct
levels were lower after treatment with a single dose of amifostine
than treatment with carboplatin alone. Decreases ofapproximately
0.8-fold were observed. A significant decrease was only observed
in the liver (P < 0.05), mainly as a result ofdecrease in the G-Pt-G
adducts. In tumour tissue a slight, insignificant increase of approx-
imately 1.1-fold was seen. When comparing these results with the
Pt-DNA adduct levels after treatment with carboplatin and three
doses of amifostine, a 1.2- to 1.6-fold increase in total Pt-DNA
adducts was observed in normal tissues, which was mainly as
a result of higher levels of Pt-G and G-Pt-G adducts. The differ-
ences in total Pt-DNA adduct levels between the single- and
the three-dose schedules were only statistically significant for
the liver samples (P < 0.005), whereas significant differences in
G-Pt-G levels were found in liver (P < 0.005), kidney (P < 0.01)
and tumour tissue (P <0.05) and in Pt-G levels in liver and
kidney (P < 0.05).
Because the Pt-DNA adduct levels were not increased propor-
tionally to the increase in total platinum, we calculated the ratio
AUCPt-DNA adducts/AUCtotal platinum'
In liver tissue this ratio was 0.23
after treatment with carboplatin alone, 0.13 after carboplatin plus
one dose of amifostine and 0.18 after carboplatin plus three doses
of amifostine. In kidney these ratios were 0.51, 0.31 and 0.40
respectively. In tumour tissue ratios of 0.56, 0.48 and 0.46 were
observed for the three treatment schedules.
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earlier observed significant potentiation ofthe anti-tumouractivity
> . when carboplatin was combined with a single dose of amifostine
00°¢:M __ (Treskes et al, 1994). Our second experiment confirmed that a poO single dose of amifostine resulted in a significant potentiation of
the anti-tumour activity of carboplatin, whereas treatment with
0 W three doses of amifostine resulted in a less pronounced increase in
the efficacy of carboplatin (Table 2, Figure 2). K)_. From our results on the potentiation of the efficacy of carbo-
platin by amifostine, we anticipated the presence of a pharmaco-
logical drug interaction. In plasma ultrafiltrate, kidney, liver and
tumour tissue the platinum concentrations were raised signifi-
cantly after treatment with amifostine. This pharmacokinetic inter-
action seemed to be dependent on the treatment schedule. Three D 5 10 15 20 25 doses of amifostine, given just before and 2 and 4 h after the
Time (h) carboplatin administration, resulted in a higher increase in total
Mean bodytemperature in non-tumour-bearing nude mice (n 3 platinum concentrations than a single dose of amifostine, given
tion with 1 x200 mgkg camiostin()orwt 3
= 0 mg kg' just before carboplatin. To investigate the consequence of the e (U) increase in total platinum on the supposed target molecule of the
anti-tumour drug, DNA in the cell, we determined the Pt-DNA
adduct levels in the same tissues and bone marrow.
rature In the normal tissues a single dose of amifostine resulted in a
small decrease in the Pt-DNA adduct levels, mainly due to the
an values of the body temperatures ofnon-tumour-bearing level of G-Pt-G adducts, despite the increase in total platinum.
lice after treatment with carboplatin alone, carboplatin in Although the observed decrease was significant only in liver, these
ation with a single dose of amifostine as well as with three results might suggest a protection by amifostine as was observed
famifostine are summarized in Figure 5. Carboplatin alone in mice (Treskes et al, 1994). After treatment with three doses of
decrease the body temperature of 370C in the 24 h amifostine higher Pt-DNA adduct levels were observed in normal
ng injection. After a single dose of amifostine the lowest tissues than with a single dose of amifostine, which was most
iture was 34.50C, which was observed I h after administra- probably due to the higher total platinum levels. These data might
lice rapidly recovered within 6 h. After three doses of indicate that, when amifostine protects against platinum-induced
ine, however, a mean body temperature of 25°C was toxicities by reduction of Pt-DNA adduct levels, this protection
d 7 h after the initiation of treatment, which only started to will be less pronounced after three doses than after a single dose of
22 h after the first injection. amifostine. However, this has never been confirmed by toxicity
studies, because only the influence of a single dose of amifostine
JSSION on the carboplatin-induced toxicities has been investigated
(Treskes et al, 1994). The small increase in Pt-DNA adduct levels
tine is an agent that protects against cisplatin-induced in normal tissues after treatment with three doses of amifostine
oxicity and carboplatin-induced myelotoxicity without was not proportional to the rise of the total platinum concentra-
g the anti-tumour activity of these platinum compounds in tions, as calculated by the ratio AUCPtDNAadducts/AUCtotalpl.tinum' The
ental human tumours (Treskes et al, ]992a, 1994). The ratios after treatment with carboplatin and amifostine were
of interference with the anti-tumour activity had already reduced when compared with the ratio after treatment with carbo-
pected from the relatively low reaction rates ofcarboplatin platin alone. This relative decrease in Pt-DNA adduct levels was
ifostine and its main metabolites (Treskes et al, 1991) as most probably due to the protective properties of amifostine. In
from the selective uptake of WR-1065 by normal tissues vitro studies have already shown that the addition ofamifostine or
)-Jones et al, 1988). However, an unexpected potentiation its metabolite WR-1065 to cisplatin resulted in lower Pt-DNA
nti-tumour activity of carboplatin was observed in nude adduct levels (Treskes et al, 1992b).
reskes et al, 1994), as has also been reported for the combi- A small but insignificant increase in the amount of Pt-DNA
if amifostine with nitrogen mustard (Valeriote and Tolen, adducts was observed in tumour tissue after treatment with one as
nd that with melphalan (Millar et al, 1982). In 25 patients well as with three doses of amifostine. Upon calculating the ratio
n-small-cell lung cancer a high response rate of 64% has AUCPt-DNAadducts/AUCOtalplatinun' a smaller decrease was observed for
ported upon treatment with cisplatin and vinblastine in carboplatin combined with one dose of amifostine than when
ition with amifostine (Schiller et al, 1996), whereas compared with the ratios in normal tissues. This might indicate
z rates of 25-30% are recorded after standard chemo- that the protective effect ofamifostine was mainly restricted to the
In another study in 21 non-small-cell lung cancerpatients, normal tissues. This is in agreement with the observed selective
it with carboplatin and amifostine was at least as active as uptake of WR-1065 in normal tissues when compared with the
it with carboplatin alone (Betticher et al, 1995). uptake in tumour tissues (Shaw et al, 1994). As a consequence, no
influence of amifostine on the anti-tumour activity of protection ofthe tumour was to be expected in the efficacy studies,
tin seemed to be dose- or schedule-dependent in our which was indeed the case. Moreover, we even found a potentia-
ents. When carboplatin was combined with three doses of tion of the anti-tumour activity, especially in the case of one dose
ne no interference with the anti-tumour activity was of amifostine. Unfortunately, the difference in potentiation
J (Table 1). These results did not correspond with the between the single and three doses of amifostine was not reflected
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by a difference in Pt-DNA adduct levels. This might be due to the
very laborious analytical method, which was the only available
assay for the detection of the four types of Pt-DNA adducts. The
assay turned out to be less precise in detecting small differences.
Furthermore, it is questionable whether all four Pt-DNA adducts
are responsible for the anti-tumour activity. When the extent of
anti-tumour activity was compared with the value of each of the
four types ofadducts then a positive relation with the major adduct
Pt-GG could be established. It is not clear whether amifostine had
an influence on the adduct formation or removal when comparing
the levels at the individual time points. Owing to the rather high
standard deviations differences between the formation and
removal of Pt-DNA adducts could not be clearly distinguished.
The reason for the observed amifostine-carboplatin pharmaco-
kinetic interaction and the difference between one and three doses
of amifostine added to carboplatin might be the observed amifos-
tine-induced hypothermia. The extreme reduction in body temper-
ature after treatment with three doses of amifostine will result in a
peripheral vasoconstriction affecting the renal clearance of carbo-
platin. This might induce an increase in the AUC values as
observed in this study. Although hypothermia leads to a reduction
in the cytotoxicity of cisplatin in vitro (Page et al, 1987), no
tumour protection was observed in our in vivo experiments. The
extreme hypothermic conditions induced by 3 x 200 mg kg-'
amifostine, however, did result in a less pronounced potentiation
of the efficacy of carboplatin. Because hypothermia is related to
the dose of amifostine, it also explains the suggested tumour
protection by the compound when given as a single dose of
400 mg kg-' (Twentyman, 1983). From other studies in which
reduction in body temperature by amifostine has been described in
Balb/c (Van der Wilt et al, 1992) and severe combined immuno-
deficient (SCID) mice (Paine et al, 1996), it appears that the extent
of this side-effect varies between different strains of mice. The
extreme hypothermia in our nude mice is most probably the reason
for the observed toxic deaths (Table 1). The extent ofhypothermia
in mice is not representative of the human situation because no
clear decrease in body temperature has been observed in patients.
Therefore, the possible influence of amifostine on the anti-tumour
activity ofcarboplatin still needs to be investigated in patients.
In conclusion, amifostine does not reduce the anti-tumour
activity of carboplatin in tumour-bearing nude mice. When given
once it even potentiates the anti-tumour activity of carboplatin.
Amifostine has an influence on the pharmacokinetics of carbo-
platin, most probably explained by altered drug distribution caused
by hypothermia, resulting in higher platinum concentrations in
normal and tumour tissues. The relative reduction in total Pt-DNA
adduct levels in these tissues suggests a selective protection of the
normal tissues, but not of the tumour tissue. Three doses of
amifostine resulted in an extreme reduction of the body tempera-
ture as well as toxic deaths and a less pronounced potentiation of
the anti-tumour activity. Extrapolating these data to the clinical
application of amifostine is difficult because the amifostine-
induced hypothermia was not observed in patients. However,
our data confirm the suggested selective protection of normal
tissues by amifostine, which makes amifostine a promising
modulating agent.
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